R. Michael Raab

R. Michael Raab began their career in 1997 as a Staff Biochemical Engineer at Merck Research Laboratories, where they were involved in process design and scale-up for Pneumovax23® and Merck’s experimental HIV vaccine. In 2000, they earned their Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where their work focused on linking gene transcription to the rates of chemical reactions in living cells. In 2002, they founded and became President of Agrivida, Inc. where they led business and technical development, funding of the company, assembly of the management and scientific teams, development of a strong intellectual property portfolio, and negotiated numerous strategic partnering agreements and collaborations. During their tenure, Agrivida grew to over 45 people, and established collaborative agreements with Syngenta, POET, and other major companies. In 2018, they joined Tiba Biotech as a Board Director.

R. Michael Raab obtained a B.S. in Chemical Engineering from the University of Wisconsin-Madison between 1991 and 1996. R. Michael then went on to earn a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology between 2000 and 2005.